I'll be staying up tonight to listen in on the GSK result. BTA has been weak, perhaps due to the dramatic reduction in reporting of Swine flu.
A key point to note is that stockpiles have been overweight Tamiflu, and that some recent vaccine cancellations were accompanied by Relenza orders thanks to the negotiating capability of GSK.
GSK have previously stated they expect a head and shoulder sales pattern. Tonight will tell us if that is confirmed.
Biotechs are impacted heavily by sentiment, and so media headlines or lack thereof do impact the price indirectly. Mix in the hand back of HCV and bingo.
Anyhow, Biota have an excellent strategy. I'd like to see them continue expansion efforts by progressing HCV, RSV themselves or look to repartner and/or start more early stage research paths... perhaps even some therapeutic vaccines.
What do the chartists see now? Is there support close to hand?
Add to My Watchlist
What is My Watchlist?